Introduction
============

Whereas the antibiotic resistance crisis in Gram-positive pathogens largely seems to be kept under control, the emergence and dissemination of antibiotic resistance in Gram-negative pathogens risk getting out of control ([@B1]; [@B24]; [@B6]; [@B15]). To gain useful information on overall trends in a specific region and alert for more effective prevention and control measures, surveillance studies based on large data sets are of particular importance in this field ([@B26]). Multivariate statistical analysis further allows studying possible relationships between antimicrobial resistance data and patient-related factors; however, there are only a limited number of studies up to now on that issue mainly dealing with *Escherichia coli*. The main findings of these studies are that susceptibilities to several antimicrobial agents are strongly depending on infection site as well as patient location (hospital/community), gender and age ([@B16]; [@B19]; [@B3]). Under the hypothesis that the same is true for *Klebsiella* sp. and *Enterobacter* sp., the aim of this study is to analyze a large amount of antibiotic resistance data (almost 39.000 isolates) from our geographical region according to patient-related factors. The application of multivariate statistical analysis enables us to detect significant associations between patient's characteristics and the percentages of resistant isolates what is of key importance to further identify possible risk factors related to antibiotic-resistant *Klebsiella* and *Enterobacter* infections.

Materials and Methods {#s1}
=====================

A total of 24.024 *Klebsiella* sp. and 14.969 *Enterobacter* sp. isolates were included in the present analysis. The study design of this retrospective observational study (data origin, laboratory methods, and statistical analysis) is largely similar to our previous report on *E. coli* ([@B3]). Data were retrieved from the Laboratory of Medical Bacteriology and Mycology of the Medical University of Graz, Austria from January 1998 to March 2014. In the event of multiple isolates from one person in a year, only the first one was considered. For each isolate, patient--related data (age, gender), patient location (community/hospital) and culture site were obtained. Culture sites were subdivided into the following categories: urinary tract (UT), genital tract (GT), wounds (WOU), respiratory tract (RES), and blood (BLO); patient age was categorized as follows: \<1, 1--9, 10--19, 20--29, 30--39, 40--49, 50--59, 60--69, 70--79, \> = 80 years.

All isolates had been tested for antibiotic susceptibilities in the routine microbiology laboratory in the same way as reported in a previous study using the disk diffusion method or a VITEK 2 system (bioMérieux, Marcy l'Etoile France) ([@B3]). From January 1st, 1998 to May 31st, 2011 results were interpreted using the criteria recommended by the Clinical and Laboratory Standards Institute (CLSI), formerly known as National Committee for Clinical Laboratory Standards (NCCLS) ([@B7]). From June 1st, 2011 results were interpreted using the criteria recommended by the European Committee on Antimicrobial Susceptibility Testing (EUCAST breakpoint tables v1.2, 2011) in its respective current version. For this study, resistance to the following 12 antibiotic agents was analyzed: amikacin (AN), amoxicillin-clavulanic acid (AMC; analyzed for *Klebsiella* sp. only), ceftazidime (CAZ), ciprofloxacin (CIP), cefotaxime (CTX), nitrofurantoin (NF; analyzed for urinary tract isolates only), gentamicin (GM), imipenem (IPM), mecillinam (MEC; analyzed for *Klebsiella* sp. urinary tract isolates only); meropenem (MEM), piperacillin/tazobactam (PT), and trimethoprim/sulfamethoxazole (SXT). Resistant and intermediate resistant isolates were combined.

Statistical Analysis
--------------------

For each of the two microbes and for each antibiotic under consideration, the absolute and relative frequencies of resistant samples were determined in total, per culture site, patient location, age group, gender and year of acquisition. In order to assess the influence of the covariates on antibiotic resistance, multivariable logistic regression analysis was performed. For binary covariates, odds ratios and 95% confidence intervals are presented and are adjusted for year of acquisition, patient gender, patient age, patient location and resistance phenotype; for culture site a model containing the aforementioned covariates as well as cultures site has been tested against a model without culture site and p values from the respective Chi-square test are presented. Statistical analysis was performed using the R package, version 3.1.1 and SPSS, version 21.0 ([@B23]; [@B11]).

Ethics Statement
----------------

The study was approved by the Ethics Committee of the Medical University of Graz (26-502 ex 13/14); patient records were anonymized prior to analysis.

Results
=======

The underlying data basis for the present analysis is shown in **Table [1](#T1){ref-type="table"}.** In total, 38.993 clinical isolates of *Klebsiella* sp. and *Enterobacter* sp. were included in the statistical analysis.

###### 

Data basis for the statistical analysis.

                       Patient gender (%)   Patient location (%)   Number of isolates          
  -------------------- -------------------- ---------------------- -------------------- ------ -------
  *Klebsiella* sp.     59.4                 40.5                   52.3                 47.7   24024
  *Enterobacter* sp.   52.8                 47.1                   44.0                 56.0   14969
  Total                                                                                        38993
                                                                                               

Species Distribution
--------------------

Within the *Klebsiella* samples, *K. pneumoniae* (61%) and *K. oxytoca* (27.1%) were the most frequently recovered species; within the *Enterobacter* samples, *E. cloacae* complex (59.2%) and *E. aerogenes* (15.4%) were the most frequently recovered species.

Overall and Annual Resistance Percentages
-----------------------------------------

**Table [2](#T2){ref-type="table"}** shows the overall resistance percentages of all tested isolates. For *Klebsiella* sp. isolates, NF (analyzed for UT isolates only) and SXT showed the highest values, for *Enterobacter* sp. the highest values were found for NF, CAZ, PT, and CTX. For *Klebsiella* sp. isolates, most antibiotics (CAZ, CTX, NF, CIP, SXT, IPM, and MEM) showed increasing percentages of resistant isolates over time (**Figure [1](#F1){ref-type="fig"}**, **Supplemental Table [S1](#SM1){ref-type="supplementary-material"}**). The percentages of resistant *Enterobacter* sp. isolates did not change considerably over the investigational period for the majority of antibiotic agents (**Supplemental Table [S1](#SM1){ref-type="supplementary-material"}**).

###### 

Overall resistance percentages of *Klebsiella* sp. and *Enterobacter* sp.

  Antibiotic   *Klebsiella* sp.   *Enterobacter* sp.           
  ------------ ------------------ -------------------- ------- ------------
  AN           3.47               366/10550            0.96    78/8094
  AMC          9.44               2264/23979                   
  CAZ          7.19               1230/17102           20.55   2341/11389
  CIP          6.43               1543/23995           5.2     778/14961
  CTX          5.76               1370/23765           19.87   2943/14811
  NF           24.43              2297/9404            30.71   1502/4891
  GM           6.66               1458/21889           2.76    392/14216
  IPM          0.89               60/6747              0.54    26/4839
  MEC          3.73               120/3220                     
  MEM          0.67               70/10511             0.28    22/7720
  PT           6.98               1270/18186           20.17   2505/12418
  SXT          10.82              2595/23990           6.22    930/14958
                                                               

AN, amikacin; AMC, amoxicillin-clavulanic acid; CAZ, ceftazidime; CIP, ciprofloxacin; CTX, cefotaxime; NF, nitrofurantoin; GM, gentamicin; IPM, imipenem; MEC, mecillinam; MEM, meropenem; PT, piperacillin/tazobactam; SXT, trimethoprim/sulfamethoxazole; %R, percentages of non-susceptible isolates.

![**Annual antibiotic resistance percentages of *Klebsiella* sp. for selected antibiotics**.](fmicb-07-00034-g001){#F1}

Resistance Percentages According to Patient-Related Data
--------------------------------------------------------

Results of the multivariate analysis of the antibiotic resistance patterns according to culture sites for both pathogens are presented in **Table [3](#T3){ref-type="table"}.** The findings reveal the lowest resistance percentages from samples originating from the male or female genital tract (GT). For *Klebsiella* sp. isolates, the highest resistance percentages for almost all antibiotics analyzed occurred in blood infections. For *Enterobacter*, the highest resistance percentages were found in isolates originating from blood (CAZ, CTX, GM, PT, SXT), and urinary tract infections (AN, CIP) (**Table [3](#T3){ref-type="table"}**).

###### 

Resistance percentages of *Klebsiella* sp. and *Enterobacter* sp. according to culture sites.

        *Klebsiella* sp. %R (n/total)   *Enterobacter* sp. %R (n/total)                                                                                                                                                     
  ----- ------------------------------- --------------------------------- ---------------- ----------------- --------------- --------- ------------------ ---------------- ----------------- ----------------- ------------ ---------
  AN    4.2 (32/766)                    0.1 (1/1648)                      1.4 (37/2657)    1.7 (48/2867)     0 (0/103)       0.022     5.7 (22/388)       0 (0/767)        0.5 (13/2629)     0.4 (10/2467)     0 (0/68)     \<0.001
  AMC   6.9 (845/12264)                 2.7 (63/2363)                     9.7 (298/3086)   10.7 (357/3347)   14.3 (17/119)   \<0.001                                                                                        
  CAZ   7.9 (486/6156)                  0.8 (16/1893)                     5.2 (152/2923)   5.9 (190/3228)    10.1 (12/119)   \<0.001   21.8 (611/2806)    6.4 (56/871)     17.9 (513/2869)   19.9 (553/2778)   36 (31/86)   \<0.001
  CIP   7.6 (937/12262)                 1.6 (39/2365)                     6.9 (213/3088)   5.9 (198/3354)    10.1 (12/119)   \<0.001   7.4 (436/5887)     0.7 (7/1075)     5 (153/3039)      4 (115/2874)      4.7 (4/86)   \<0.001
  CTX   4.3 (518/12044)                 1 (24/2364)                       5.2 (161/3084)   5.6 (189/3350)    10.9 (13/119)   0.011     19.3 (1111/5747)   6.8 (73/1076)    18.2 (553/3038)   19.7 (564/2865)   36 (31/86)   \<0.001
  GM    3.5 (351/10162)                 0.7 (17/2363)                     3.9 (119/3087)   5.9 (198/3352)    4.2 (5/119)     \<0.001   1.7 (86/5144)      0.1 (1/1076)     1.2 (37/3039)     1.3 (36/2872)     2.3 (2/86)   \<0.001
  IPM   0.2 (2/1110)                    0 (0/814)                         0.8 (12/1495)    1.1 (20/1755)     3.7 (3/81)      0.013     0.2 (1/583)        0 (0/306)        0.5 (7/1380)      0.3 (5/1476)      0 (0/54)     0.025
  MEM   0.2 (5/2101)                    0 (0/1124)                        0.7 (15/2286)    1 (24/2414)       3.7 (4/108)     \<0.001   0.3 (3/931)        0 (0/580)        0.2 (4/2344)      0.1 (3/2076)      0 (0/80)     0.003
  PT    5.9 (421/7102)                  1.4 (30/2121)                     7.8 (230/2948)   9.1 (288/3156)    12.7 (15/118)   \<0.001   16.3 (805/4934)    22.7 (204/899)   22.6 (539/2390)   23.4 (567/2426)   38 (27/71)   \<0.001
  SXT   12.6 (1551/12263)               4.2 (100/2365)                    8 (248/3085)     7.2 (242/3354)    9.2 (11/119)    \<0.001   6 (354/5881)       6.2 (67/1076)    6 (182/3041)      6.3 (182/2873)    14 (12/86)   0.221
                                                                                                                                                                                                                            

UT, urinary tract; GT, genital tract; WOU, wounds; RES, respiratory tract; BLO, blood; AN, amikacin; AMC, amoxicillin-clavulanic acid; CAZ, ceftazidime; CIP, ciprofloxacin; CTX, cefotaxime; NF, nitrofurantoin; GM, gentamicin; IPM, imipenem; MEM, meropenem; PT, piperacillin/tazobactam; SXT, trimethoprim/sulfamethoxazole.

a

The p-values stem from a goodness-of-fit test comparing a model including all variables against a reduced model including all variables except for culture site.

Antibiotic resistance patterns in relation to patient gender are shown in **Table [4](#T4){ref-type="table"}.** Resistance percentages for almost all antibiotic agents analyzed are higher in male patients. A significant difference can be shown for all antibiotics except for AN for *Klebsiella* sp. isolates and for AN, GM, IPM, MEM, and PT for *Enterobacter* sp., respectively. Antibiotic resistance patterns in relation to patient location are shown in **Table [5](#T5){ref-type="table"}.** Resistance percentages for almost all antibiotic agents analyzed are significantly higher in hospital treated patients. This is true for both *Klebsiella* sp. and *Enterobacter* sp. isolates.

###### 

Antibiotic resistance percentages of *Klebsiella* sp. and *Enterobacter* sp. according to patient gender.

        *Klebsiella* sp. %R (n/total)   *Enterobacter* sp. %R (n/total)                                                               
  ----- ------------------------------- --------------------------------- --------------------- ------------------ ------------------ ---------------------
  AN    3.2 (174/5396)                  3.7 (192/5141)                    1.16 \[0.95, 1.44\]   0.8 (28/3731)      1.1 (50/4355)      1.43 \[0.89, 2.34\]
  AMC   7.4 (1053/14245)                12.5 (1210/9715)                  1.78 \[1.63, 1.94\]                                         
  CAZ   5.9 (552/9398)                  8.8 (677/7688)                    1.55 \[1.38, 1.74\]   17.7 (990/5598)    23.3 (1350/5782)   1.13 \[1.03, 1.25\]
  CIP   4.5 (647/14248)                 9.2 (895/9728)                    2.13 \[1.92, 2.37\]   3.3 (263/7899)     7.3 (515/7050)     2.2 \[1.88, 2.57\]
  CTX   4.3 (611/14093)                 7.9 (758/9653)                    1.88 \[1.68, 2.1\]    17.4 (1361/7812)   22.6 (1580/6987)   1.1 \[1.01, 1.2\]
  NF    22.4 (1392/6208)                28.3 (905/3196)                   1.37 \[1.24, 1.51\]   28.2 (837/2972)    34.7 (665/1919)    1.23 \[1.09, 1.4\]
  GM    4.8 (613/12791)                 9.3 (844/9079)                    2.04 \[1.83, 2.27\]   2.3 (170/7416)     3.3 (222/6788)     1.11 \[0.9, 1.38\]
  IPM   0.5 (17/3464)                   1.3 (43/3273)                     2.7 \[1.57, 4.87\]    0.5 (12/2255)      0.5 (14/2578)      0.8 \[0.37, 1.76\]
  MEC   3 (60/2012)                     5 (60/1208)                       1.62 \[1.11, 2.36\]                                         
  MEM   0.4 (19/5174)                   1 (51/5326)                       2.07 \[1.24, 3.61\]   0.3 (9/3509)       0.3 (13/4206)      1 \[0.43, 2.43\]
  PT    5.3 (545/10257)                 9.2 (724/7912)                    1.35 \[1.19, 1.52\]   19.7 (1286/6523)   20.7 (1216/5887)   1.01 \[0.93, 1.11\]
  SXT   9.3 (1321/14245)                13.1 (1273/9726)                  1.3 \[1.19, 1.43\]    5.8 (457/7897)     6.7 (472/7049)     1.16 \[1.01, 1.33\]
                                                                                                                                      

AN, amikacin; AMC, amoxicillin-clavulanic acid; CAZ, ceftazidime; CIP, ciprofloxacin; CTX, cefotaxime; NF, nitrofurantoin; GM, gentamicin; IPM, imipenem; MEC, mecillinam; MEM, meropenem; PT, piperacillin/tazobactam; SXT, trimethoprim/sulfamethoxazole. OR, odd ratio

###### 

Antibiotic resistance percentages of *Klebsiella* sp. and *Enterobacter* sp. according to patient location.

        *Klebsiella* sp. %R (n/total)   *Enterobacter* sp. %R (n/total)                                                               
  ----- ------------------------------- --------------------------------- ---------------------- ----------------- ------------------ -----------------------
  AN    0.3 (10/2894)                   4.6 (356/7656)                    4.18 \[2.24, 8.71\]    0.6 (11/1782)     1.1 (67/6312)      1.39 \[0.74, 2.83\]
  AMC   4.8 (602/12557)                 14.6 (1662/11422)                 2.43 \[2.18, 2.71\]                                         
  CAZ   4.5 (303/6703)                  8.9 (927/10399)                   1.32 \[1.04, 1.69\]    10.2 (369/3607)   25.3 (1972/7782)   2.97 \[2.63, 3.37\]
  CIP   5.6 (700/12558)                 7.4 (843/11437)                   1.08 \[0.96, 1.23\]    4.5 (297/6587)    5.7 (481/8374)     1.22 \[1.05, 1.43\]
  CTX   2.7 (335/12552)                 9.2 (1035/11213)                  2.39 \[1.8, 3.18\]     11.8 (775/6584)   26.4 (2168/8227)   2.67 \[2.44, 2.93\]
  NF    21 (1376/6557)                  32.3 (921/2847)                   1.77 \[1.59, 1.96\]    26.1 (872/3339)   40.6 (630/1552)    1.82 \[1.6, 2.07\]
  GM    2 (205/10465)                   11 (1253/11424)                   2.86 \[2.4, 3.42\]     0.7 (40/5847)     4.2 (352/8369)     4.48 \[3.23, 6.39\]
  IPM   0.2 (4/1863)                    1.1 (56/4884)                     2.55 \[1.01, 8.59\]    0 (0/1032)        0.7 (26/3807)      ^∗^
  MEC   3.3 (78/2393)                   5.1 (42/827)                      1.3 \[0.87, 1.93\]                                          
  MEM   0.2 (4/2508)                    0.8 (66/8003)                     5.14 \[2.09, 17.09\]   0.1 (1/1534)      0.3 (21/6186)      5.79 \[1.18, 104.62\]
  PT    3.4 (266/7892)                  9.8 (1004/10294)                  2.71 \[2.34, 3.14\]    18.3 (956/5219)   21.5 (1549/7199)   1.2 \[1.09, 1.32\]
  SXT   9.5 (1190/12556)                12.3 (1405/11434)                 0.95 \[0.86, 1.05\]    5.9 (387/6582)    6.5 (543/8376)     1.05 \[0.91, 1.21\]
                                                                                                                                      

AN, amikacin; AMC, amoxicillin-clavulanic acid; CAZ, ceftazidime; CIP, ciprofloxacin; CTX, cefotaxime; NF, nitrofurantoin; GM, gentamicin; IPM, imipenem; MEC, mecillinam; MEM, meropenem; PT, piperacillin/tazobactam; SXT, trimethoprim/sulfamethoxazole.

∗

Not estimable because of 0 resistant isolates in outpatient group. OR, odd ratio

Regarding the association between antibiotic resistance percentages of *Klebsiella* sp. and *Enterobacter* sp. isolates and patient age, the majority of antibiotics show a balanced distribution except for CIP where a constant increase with age can be shown for both pathogen groups (**Figure [2](#F2){ref-type="fig"}**).

![**Percentages of antibiotic resistance of *Klebsiella* sp. **(A)** and *Enterobacter* sp. **(B)** to CIP according to patient age**.](fmicb-07-00034-g002){#F2}

Discussion
==========

We here report an observational study whose aim is to analyze the susceptibility of Austrian clinical *Klebsiella* sp. and *Enterobacter* sp. isolates linked to patient-related data. The underlying database for this statistical analysis covers the period from 1998 to 2014. A major limitation of the present study is that it was not possible to link the data to severity of disease and patient outcome as these data were not available. Additionally, information about the patient's length of the hospital stay was not included in the analysis which would have been useful for the classification as hospital or community acquired infections. In the present work, infections were categorized depending on the patient's location at the moment the clinical sample was obtained. The passage from CLSI to EUCAST guidelines in 2011 in Austria may further bias data comparability. Several authors have reported an increase of antibiotic resistance rates for certain *Enterobacteriaceae* species/drug combinations following EUCAST breakpoints implementation ([@B10]; [@B25]). However, we did not observe any artificial rise of antibiotic resistance at that time indicating that the change of interpretation criteria does not apparently impact the results of the large data set analyzed.

In general, surveillance is a substantial basis in the combat against antimicrobial resistance in both community and hospital settings; a large number of resistance surveillance reports thus exist about *Klebsiella* sp. and *Enterobacter* sp. isolates from various parts of the world describing the current resistance situation ([@B13]; [@B4]; [@B9]; [@B2]; [@B14]). Furthermore, studies dealing with the association of antimicrobial resistance data and specific factors depending on the host are of major importance with regard to the identification of possible risk factors related to antibiotic-resistant infections. Several studies aimed to find various patient demographics and clinical factors associated with the presence of antibiotic-resistant *Enterobacteriaceae* isolates, however, most of them involve particular infections, patient cohorts, anatomic sites or specific resistance problems. These studies thus mostly cover a small amount of isolates consequently limiting statistical data processing ([@B21]; [@B18]; [@B12]; [@B20]; [@B22]). Here we present a comprehensive statistical analysis on associations between patient-related data and the percentages of antibiotic resistant *Klebsiella* sp. and *Enterobacter* sp. isolates referring on a large database with almost 39.000 isolates from Austria. The main findings of this study are (i) a marked difference of antibiotic susceptibility rates between different infection sites for both *Klebsiella* sp. and *Enterobacter* sp., (ii) significantly greater percentages of resistant isolates among both *Klebsiella* sp. and *Enterobacter* sp. in male patients compared to female patients and (iii) significantly greater percentages of resistant isolates among both *Klebsiella* sp. and *Enterobacter* sp. isolates from hospital-derived samples compared to samples from the community.

To our knowledge, this is the first report to compare percentages of antibiotic resistant *Klebsiella* sp. and *Enterobacter* sp. isolates from different infection sites within a specific region. The highest resistance percentages for the majority of antibiotics analyzed can be shown for both pathogen groups originating from blood infections. This is in accordance with previous statistical analyses on the association of the infection site and *Escherichia coli* susceptibility profiles ([@B19]; [@B3]). As reported for *Escherichia coli*, *Klebsiella* sp. and *Enterobacter* sp. isolates originating from the GT generally show the lowest resistance percentages indicating that detection from this culture site often represents the normal patient flora. Interestingly, antibiotic-resistant *Klebsiella* sp. and *Enterobacter* sp. infections within our study collection derive mostly from men. The same association between patient sex and antibiotic resistance was previously shown for *Escherichia coli*, however, the underlying cause remains as yet largely unclear ([@B16]; [@B19]; [@B3]). Similar to the results from several other studies dealing with antibiotic resistance percentages of *Enterobacteriaceae* in community and hospital settings we found significantly greater resistance rates for both pathogen groups amongst the hospital-derived isolates suggesting that the problem of antibiotic resistance amongst Gram-negative pathogens is still focused on hospital settings in our region ([@B5]; [@B8]; [@B17]).

Conclusion
==========

Our statistical data analysis clearly indicates a strong association between patient characteristics (gender, localization, infection site) and *Klebsiella* sp. and *Enterobacter* sp. susceptibility profiles. To gain further insight in the correlation of bacterial antibiotic resistance and its host, additional studies analyzing large databases of microbiological information are of crucial importance ultimately influencing local antimicrobial therapy guidelines.
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**TABLE S1 \| Annual resistance percentages of *Klebsiella* sp. and *Enterobacter* sp.**
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Click here for additional data file.
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